GlassScriptPhysician profile
Sharla Shipman
NPI 1225034275
$2,416.36
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $107 · 2021: $20.89 · 2022: $981 · 2023: $369 · 2024: $306 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.68 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $620.52 | 2022 | |
| Abbvie INC. | $312.06 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $197.34 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $146.42 | 2022 | |
| Pfizer INC. | $121.05 | 2022-2024 | |
| Medtronic, INC. | $110.78 | 2022-2024 | Ligasure, Truclear |
| Daiichi Sankyo INC. | $102.51 | 2019-2023 | Injectafer |
| Mayne Pharma Commercial LLC | $77.85 | 2021-2025 | |
| Hologic Sales and Service, LLC | $66.63 | 2020-2024 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Organon LLC | $60.42 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $58.81 | 2023-2025 | Myfembree |
| Biogen, INC. | $57.09 | 2024 | Zurzuvae |
| Agile Therapeutics, INC. | $52.04 | 2023-2024 | Twirla |
| Pharmacosmos Therapeutics INC. | $42.38 | 2023-2024 | Monoferric |
| Baxter Healthcare | $41.59 | 2023 | Perclot |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $37.03 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $30.00 | 2024-2025 | Femlyv |
| Allergan, INC. | $30.00 | 2019 | |
| Covidien LP | $29.84 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $25.51 | 2019 | |
| Monaghan Medical Corporation | $21.87 | 2023 | Aerobika |
| Bayer Healthcare Pharmaceuticals INC. | $20.06 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.79 | 2022 | |
| Therapeuticsmd, INC. | $17.10 | 2022 | |
| Coopersurgical, INC. | $15.48 | 2023 | Paragard T 380a |
| Shield Therapeutics INC | $15.16 | 2025 | |
| Amag Pharmaceuticals, INC. | $14.65 | 2019 | |
| Merck Sharp & Dohme LLC | $14.44 | 2025 | Gardasil 9 |
| Minerva Surgical, INC | $13.47 | 2019 | |
| Radius Health, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharla Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.